NONOF News and Press, Novo-Nordisk A/S From 01/10/24

2024-01-10 12:09:02 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...

2024-01-10 11:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. International growth e...

2024-01-09 14:52:04 ET Shares of contract manufacturer Catalent ( NYSE: CTLT ) traded higher on Tuesday to reach the highest level in more than four months after its CEO, Alessandro Maselli, highlighted the company’s production capacity related to GLP-1 class of weight loss d...

2024-01-09 14:36:07 ET Novo Nordisk A/S (NVO) J.P. Morgan 42nd Annual Healthcare Conference January 09, 2024 12:45 PM ET Company Participants Lars Fruergaard Jorgensen - President & Chief Executive Officer Conference Call Participants Richard Vosser - JPM...

2024-01-09 11:40:35 ET More on Madrigal, Viking, etc. Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap Madrigal Pharmaceuticals: Preparing For Resmetirom's Commerci...

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

2024-01-04 10:07:28 ET More on Eli Lilly Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) Eli Lilly: Long Path To A Trillion Lilly to offer at-home delivery for wei...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2024-01-02 11:12:57 ET Summary Madrigal Pharmaceuticals, Inc. stock has rallied 70% since late October due to a decrease in competitive concerns and a large secondary offering. The company's candidate resmetirom is expected to be the first approved therapy for NASH in March 2024. ...